HPV vaccination catch up program: Utilisation by young Australian women

Australian Family Physician

Volumn 38, Issue 1-2, 2009, Pages 72-76

  Weisberg, Edith ^a   Bateson, Deborah ^a   McCaffery, Kirsten ^b   Skinner, S Rachel ^c  

^a Sydney Centre for Reproductive Health Research   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; ATTITUDE TO HEALTH; AUSTRALIA; DISEASE TRANSMISSION; EPIDEMIOLOGY; FEMALE; HUMAN; VIRUS INFECTION;

ADOLESCENT; ADULT; AUSTRALIA; FEMALE; HEALTH CARE SURVEYS; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; YOUNG ADULT;

EID: 60149101719     PISSN: 03008495     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and highgrade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621-32.
2. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95:1459-66.
3. Australian Institute of Health and Welfare. Cervical screening in Australia 2005-2006. Cancer series no. 41. Cat. No. CAN 36 Canberra: AIHW, 2008.
4. Monk BJ, Tewari KS. The spectrum and clinical sequelae of human papillomavirus infection. Gynecol Oncol 2007;107(Suppl 1):S6-13.
5. Australian Government Department of Health and Ageing. Available at www.imunise.health.gov.au [Accessed 16 July 2008].
6. Britt H, Miller GC, Charles J, et al. Problems managed, changes over time, 1998-1999 to 2000-2007. General practice activity in Australia 2006-2007, p. 21.
7. Regan DG, Philip DJ, Hocking JS, Law MG. Modelling the population-level impact of vaccination on the transmission of human papillomavirus type 16 in Australia. Sex Health 2007;4:147-63.
8. Gillison ML, Koch WM, Capone RB, et al. Evidence for a causal association between human papillomavirus and a subset of head and neck cancers. J Natl Cancer Inst 2000;92:709-20.
9. Nielson CM, Harris RB, Dunne EF, et al. Risk factors for anogenital human papillomavirus infection in men. J Infect Dis 2007;196:1137-45.
10. Kjaer SK, Tran TN, Sparen P, et al. The burden of genital warts: a study of nearly 70,000 women from the general female population in the 4 Nordic countries. J Infect Dis 2007;96:1447-54.
11. Chesson HW, Forhan SE, Gottlieb SL, Markowitz LE. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 2008;26:4513-8.
12. Giuliano AR. Human papillomavirus vaccination in males. Gynecol Oncol 2007;107(Suppl 1):S24-6.
13. Future II Study Group. Prophylactic efficacy of a quadrivalent human papillomavirus (HPV) vaccine in women with virological evidence of HPV infection. J Infect Dis 2007;196:1438-46.
14. Wright TC Jr, Hug WK, Monk BJ, Smith JS, Ault K, Herzog TJ. Age considerations when vaccinating against HPV. Gynecol Oncol 2008;109(2 Suppl):S40-7.
15. Evans BA, Kell PD, Bond RA, MacRae KD. Heterosexual relationships and condomuse in the spread of sexually transmitted diseases in women. Genitourin Med 1995;71:291-4.
16. Richter DL, Valois RF, McKeown RE, Vincent ML. Correlates of condom use and number of sexual partners among high school adolescents. J Sch Health 1993;63:91-6.